沃尼妙林说明书
- 格式:pdf
- 大小:117.57 KB
- 文档页数:3
普沃康
[通用名]:盐酸沃尼妙林
[主要成分]:沃尼妙林
[产品特点]:
1、抗菌谱广,对治疗支原体感染有特效。
2、工艺独特、适口性好。
3、流动性好、应用方便
4、安全低毒、无耐药性
5、无残留,停药期仅一天。
[适应症]:有效防治猪喘气病、传染性胸膜肺炎、链球菌病、痢疾、增生性肠炎等疾病。
[注意事项]:
1、猪使用沃尼妙林期间或用药前后5天内不要给离子载体之类的药物,如盐霉素、莫能菌素和甲基盐霉素。
2、在混合沃尼妙林预混剂和接触含沃尼妙林的饲料时,应该避免直接接触皮肤和粘膜。
3、产品开封后请注意密封保存。
[不良反应]:超剂量使用,影响猪的平均增长和饲料报酬率。
[停药期]:猪1日。
[规格]:10%、50%。
[有效期]:18个月。
兽药通团购商城。
盐酸沃尼妙林本品是截短侧耳素类的衍生物,属于双萜类半合成抗生素,与泰妙菌素是同系物.沃尼妙林的抗菌机理与泰妙菌素相似,即与病原微生物核糖体上的50S亚基结合,抑制蛋白质的合成。
即通过与病原微生物核糖体23S RNA的V区相互作用,阻止了肽基转移酶正确定位于tRNA的CCA-末端,从而抑制了病原微生物蛋白质的合成,导致其死亡2楼沃尼妙林(Valnemulin)氟沃尼妙林(Valnemulin)是新一代截短侧耳素(pleuromutilin)类半合成抗生素,属二萜烯类,与泰妙菌素属同一类药物,是动物专用抗生素。
主要用于防治猪、牛、羊及家禽的支原体病和革兰氏阳性菌感染。
1999年由欧共体批准用于预防与治疗由猪痢疾短螺旋体(Brachyspira hyodysenteriae)感染引起的猪痢疾和由肺炎支原体感1月被欧共体)——生长1.01.11.1.21.1.3 八氢-5, 8-1.1.41.1.5174-177℃。
1.2主要是抑菌,1.3药动学研究猪口服沃尼妙林迅速吸收,吸收率大于90%,给药后1-4小时达到血浆最高浓度,血浆半衰期1.3-2.7小时。
口服单剂量10 mg/kg体重沃尼妙林盐酸盐,达峰时间1.85小时,达峰浓度1.29 μg/ml,曲线下面积(AUC)5.5 8 μg/ml/小时。
当剂量为25mg/kg体重时,达峰时间2.9小时,达峰浓度2.67 μg/ml,曲线下面积(AUC)18.23 μg/ml/小时;当剂量为50mg/kg体重时,达峰时间4.15小时,达峰浓度6.23 μg/ml,曲线下面积(AUC)67.3 μg/ ml/小时;血浆浓度与给药剂量呈线性关系。
重复给药后,发生轻微积累,但5小时内平稳。
每天2次,5 mg/kg 体重重复给药,血浆浓度维持稳定水平7.5天。
因为明显的首过效应,血浆浓度受给药方法的影响。
但沃尼妙林主要集中在组织中,特别是在肺和肝脏组织中。
15个剂量放射性标志的沃尼妙林最后1次给与猪后5天,肝脏浓度大于6倍血浆浓度。
动物专用抗生素延胡索酸泰妙菌素和盐酸沃尼妙林的研究应用赵才兵于文光杨茂锋山东胜利股份有限公司2012年3月23日,美国纽约曼哈顿联邦法院西奥多〃卡茨(The odoreKatz)法官作出判决,要求美国食品药品监督管理局(FDA)采取措施禁止在动物饲料中使用常用抗生素,以应对潜在的食物安全问题。
抗生素耐药性等问题再次被推上风头浪尖。
截短侧耳素衍生物——延胡索酸泰妙菌素和盐酸沃尼妙林是动物专用抗生素,对支原体、胸膜肺炎防线杆菌、螺旋体、胞内劳森菌和部分革兰氏阳性菌有良好的抗菌活性,同时该药在动物物体内吸收迅速、靶组织药物浓度较高、分解代谢较为完全、基本没有环境危害,在养殖体系的疾病防控中具有重要的作用。
一、理化性质延胡索酸泰妙菌素(Tiamulin hydrogen famarate)是泰妙菌素的延胡索酸盐,白色或类白色结晶性粉末;吸入能够产生强烈的刺激、味苦;在甲醇或乙醇中易溶,在水中溶解,在丙酮中略溶,在已烷中几乎不溶;比旋度+24°~+27°;pH值3.1~4.1;分子量601,分子式为C28H47NO4S²C4H4O4。
盐酸沃尼妙林(Valnemulin hydrochloride)是沃尼妙林的盐酸盐,白色或类白色无定型粉末;味苦、刺激性较强;在水、乙醇中易溶,在叔丁基甲醚中几乎不溶;比旋度+15.5°~+18.0°,pH在3.0~6.0之间;分子量601,分子式 C31H53ClN2O5S。
二、作用机理盐酸沃尼妙林和延胡索酸泰妙菌素属于双萜烯类化合物,且具有三环刚性结构,其最重要的特征是具有八元环。
Egger(1976)通过合成的66 种不同截短侧耳素衍生物的比较和研究,截短侧耳素分子中五元环上的羰基和C-11 位上的羟基对其活性来说是必需的;环外乙烯基的氢化产物与其含未饱和功能基团的母体物质具有相同的活性;C-14 位上带有未酯化的游离羟基基团的化合物无抗菌活性;C-14 位上酰基的性质对衍生物抗菌活性的产生及强弱具有重要的意义。
盐酸沃尼妙林本品是截短侧耳素类的衍生物,属于双萜类半合成抗生素,与泰妙菌素是同系物.沃尼妙林的抗菌机理与泰妙菌素相似,即与病原微生物核糖体上的50S亚基结合,抑制蛋白质的合成。
即通过与病原微生物核糖体23S RNA的V区相互作用,阻止了肽基转移酶正确定位于tRNA的CCA-末端,从而抑制了病原微生物蛋白质的合成,导致其死亡2楼沃尼妙林(Valnemulin)氟沃尼妙林(Valnemulin)是新一代截短侧耳素(pleuromutilin)类半合成抗生素,属二萜烯类,与泰妙菌素属同一类药物,是动物专用抗生素。
主要用于防治猪、牛、羊及家禽的支原体病和革兰氏阳性菌感染。
1999年由欧共体批准用于预防与治疗由猪痢疾短螺旋体(Brachyspira hyodysenteriae)感染引起的猪痢疾和由肺炎支原体感染引起的猪地方性肺炎。
它是第一个全欧洲批准的兽用药物预混剂,被列为兽用处方药。
2004年1月被欧共体批准预防由结肠菌毛样短螺旋体(Brachyspira pilosicoli)感染引起的猪结肠螺旋体病(结肠炎colitis)——生长猪的一种温和形式的下痢和治疗由细胞内劳森菌感染引起的猪增生性肠病(回肠炎ileitis)。
猪痢疾短螺旋体、结肠菌毛样短螺旋体和细胞内劳森菌是大多数生长猪肠炎的罪魁祸首。
1.0药物基础知识介绍1.1药物学知识1.1.2 通用名:沃尼妙林1.1.3 化学名:((2-((R)-2-氨基-3-甲基丁酰氨基)-1,1-二甲基乙基)巯基)乙酸,(3aS,4R,5S,6S,8R,9R,9aR,10R)-八氢-5, 8-二羟基-4,6,9,10-四甲基-6-乙烯基-3a,9-丙烷-3aH-环戊环辛烯-1(4H)-酮-8-酯1.1.4分子式 C31H52N2O5S ;相对分子量:564.81.1.5性状:白色结晶粉末,极微溶于水(160mgl-),溶于甲醇、乙醇、丙酮、氯仿,其盐酸盐溶于水,熔点174-177℃。
新型兽用抗菌药物———沃尼妙林核心提示:沃尼妙林是20世纪90年代中期国外批准新上市的一种动物专用抗生素,用于治疗猪、牛、羊、家禽等霉形体病及细菌性疾病。
作为一种新型抗菌药物,沃尼妙林具有抗菌活性强、低残留、休药期短等特点。
抗菌机理及抗...沃尼妙林是20世纪90年代中期国外批准新上市的一种动物专用抗生素,用于治疗猪、牛、羊、家禽等霉形体病及细菌性疾病。
作为一种新型抗菌药物,沃尼妙林具有抗菌活性强、低残留、休药期短等特点。
抗菌机理及抗菌活性沃尼妙林的抗菌机理与泰妙菌素相似,即与病原微生物核糖体上的50S亚基结合,抑制蛋白质的合成。
即通过与病原微生物核糖体相互作用,从而抑制了病原微生物蛋白质的合成,导致其死亡。
沃尼妙林抗菌活性很强,对各种动物不同种类的霉形体、支原体、链球菌、金葡菌、放线杆菌、巴氏杆菌、猪痢疾密螺旋体及结肠菌毛样螺旋体等都有良好的抗菌活性。
对猪肺炎霉形体的MIC值是每毫升0.005微克,是泰妙菌素的100倍,恩诺沙星的20倍;对猪滑液霉形体的MIC值为每毫升0.0001微克~0.00025微克,是泰妙菌素的20倍~25倍,恩诺沙星的400倍~500倍。
体外抑菌试验表明,猪痢疾密螺旋体及结肠菌毛样螺旋体已对泰妙菌素产生耐药性,而对沃尼妙林依然敏感,对猪痢疾密螺旋体MIC值为每毫升0.016微克~1微克,是泰妙菌素的2倍,克林霉素的16倍,林可霉素的64倍,是恩诺沙星、泰乐菌素的256倍。
药物代谢动力学研究表明,沃尼妙林内服吸收迅速,血药浓度达峰时间在1小时~4小时,血浆浓度与给药剂量呈线性关系。
生物利用度在90%以上。
体内分布广泛,在肺和肝脏组织中药物浓度高出血浆浓度几倍。
药物残留试验表明,只需休药1天,即可代谢到对人体无害的水平。
特殊毒性试验表明,沃尼妙林无繁殖毒性、致畸性、致突变性、致癌性;重复剂量试验表明,沃尼妙林对免疫系统无任何影响。
可见沃尼妙林具有明确的抗菌机理、极低的MIC值、极强的抗菌活性、低毒、低残留,主要浓集于肺部等特点,是治疗各种霉形体引起的肺部疾病的理想药物。
新兽药盐酸沃尼妙林研究进展及使用吴广辉方炳虎刘小艳陈良柱(广东大华农动物保健品有限公司,广东新兴 5 2 7 4 0 0 华南农业大学兽医学院,广东广州 5 1 0 6 4 2 )盐酸沃尼妙林是新一代截短侧耳素类半合成的动物专用抗生素,属二萜烯类,与泰妙菌素属同一类药物。
国外主要用于防治猪、牛、羊及家禽的支原体病和革兰氏阳性菌感染,具有广谱、抗菌活性强、药动学特征优良、残留低、安全等特点。
1 9 9 9年由欧共体批准用于预防与治疗由猪痢疾短螺旋体感染引起的猪痢疾和由肺炎支原体感染引起的猪地方性肺炎。
2 0 0 4年 1月被欧共体批准预防由结肠菌毛样短螺旋体感染引起的猪结肠螺旋体病 (结肠炎)和治疗由细胞内劳森菌感染引起的猪增生性肠病(回肠炎) 。
(一)药物学1.中文正式品名:盐酸沃尼妙林2.英文名:Va l n e mu l i n Hyd r o c h o l o r i d e3. 汉语拼音名:Ya n s u a n Wo n i mi ao l i n4. 分子式:C3 1 H5 2 N2 S 05· HC1 ,相对分子量:6 0 1.3 0。
5. 化学名:( (2一 ( (R)一2一氨基一3一甲基丁酰氨基)一1, l -二甲基乙基)巯基)乙酸,(3 a S,4 R,5 S,6 S,8 R,9 R,9 a R,1O R)一八氢一5 ,8二羟基- 4,6 ,9 ,1 0 -四甲基一6 一乙烯基-3 a,9 -丙烷一3 a H一环辛烯一1 (4 H)~酮- 8 -酯盐酸盐。
6. 性状:白色或淡黄色结晶性粉末,有吸湿性,在水、无水乙醇中易溶,在叔丁基甲醚中几乎不溶。
比旋度为+1 5.5。
~+1 8.0。
7 .酸度:p H值为 3.0~6.0。
(二)药理1. 药效学:本品抗菌谱广,对革兰氏阳性菌、阴性菌、厌氧菌、支原体和螺旋体均有效,金黄色葡萄球菌、链球菌、肺炎支原体、滑液囊霉形体、猪胸膜肺炎放线杆菌、猪痢疾短螺体、结肠菌毛样短螺旋体、细胞内劳森菌等均有很强的抑制作用。
7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United KingdomTelephone +4+4infww© European Medicines Agency, 2011. Reproduction is authorised provided the source is acknowledged.EMA/486934/2006EMEA/V/C/042EPAR summary for the publicEconorValnemulinThis document is a summary of the European Public Assessment Report. Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.This document cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the Scientific Discussion (also part of the EPAR).What is Econor?Econor is available as a premix for medicated feedingstuff for pigs, and as an oral powder for pigs. The premix is mixed into pig feed by an authorised feed mill and the resulting “medicated feeding stuff” is then distributed to the farmer to treat a large number of pigs. The oral powder is mixed into pig feed by the pig owner and is used to treat individual pigs.Econor premix contains the active substance valnemulin at 0.5%, 1%, 10%, and 50%. Not all concentrations may be available in each country.Econor oral powder contains the active substance valnemulin at 10%.What is Econor used for?Econor is an antibiotic.It is used in pigs to treat and / or to prevent a number of infectious diseases that are caused by bacteria and affect the lungs (i.e. Swine Enzootic Pneumonia) or the intestinal tract (i.e. Swine Dysentery, Porcine Proliferative Enteropathy (ileitis) or Porcine Colonic Spirochaetosis (colitis)).Econor improves the health and weight of the treated pigs, but may not eliminate completely the bacteria that caused lung infection.Econor is mixed into pig food. The dose and length of treatment depends on the condition for whichit is being used. For details, please see the Package Leaflet.How does Econor work?The active substance of Econor is valnemulin, an antibiotic of the pleuromutilin group. It works by blocking the production of proteins in the bacteria’s ribosomes and inhibits the growth of bacteria. Valnemulin is active against a range of bacteria including those responsible for the intestinal and respiratory diseases listed above.How has Econor been studied?The antimicrobial effectiveness of valnemulin against bacteria causing the claimed diseases in pigs was studied in microbiological laboratories.The efficacy of Econor in the claimed indications was investigated in challenge studies (i.e. pigswere artificially infected with the bacteria) or in field studies (i.e. natural infections under farm conditions). The field studies were carried out on a large number of farms in various European countries involving various breeds and crossbreeds of pigs.Econor was used either to treat animals that were already affected by a disease or to prevent the outbreak of the disease in pigs in contact with diseased animals as well as on farms with a historyof repeatedly re-occurring disease.During the clinical trials, pigs were only fed with medicated feedingstuff containing valnemulin in different concentrations (depending on the disease) for up to 4 weeks (depending on the disease). Efficacy of Econor was compared with the efficacy of an oral treatment with other antibiotics approved in the EU for the indication or with animals that did not receive any medication.What benefit has Econor shown during the studies?In the studies in the treatment and prevention of swine dysentery, Econor in feed at a dose of 3-4mg valnemulin/kg bodyweight/day (i.e. 75 mg/kg feed) for at least 7 days successfully treatedswine dysentery. Econor at a dose of 1-1.5 mg valnemulin/kg bodyweight/day (i.e. 25mg/kg feed) effectively prevented the development of the disease.In the studies in the treatment and prevention of swine enzootic pneumonia, Econor in feed at adose of 10-12 mg valnemulin/kg bodyweight (i.e. 200 mg/kg feed) reduced lung lesions, improved clinical signs and pig growth rates. However, infection with Mycoplasma hyopneumoniae was not eliminated.EconorPage 2/3EconorPage 3/3In the prevention of porcine colonic spirochaetosis (colitis), Econor in feed at a dose of 1-1.5mg valnemulin/kg bodyweight/day (i.e. 25 mg/kg feed) was effective in controlling the clinical signs and prevented weight loss caused by the disease in untreated pigs.For the treatment of porcine proliferative enteropathy (ileitis), Econor in feed at a dose of 3-4 mg valnemulin/kg bodyweight/day (i.e. 75 mg/kg feed) for 10 days improved the clinical condition of the pigs, reduced diarrhoea and improved productivity.What are the side effects of Econor?Serious adverse drug reactions following the use of Econor are mainly associated with breeds and cross breeds of Danish and/or Swedish Landrace. Extreme care should, therefore, be taken when using Econor in pigs of Scandinavian origin.Affected pigs are pyrexic (have a high temperature), have a lack of appetite; in severe cases they might become uncoordinated and remain lying down. Some pigs may also suffer oedema (swelling caused by fluid) or erythema (redness) on the hindquarters, and palpebral (eyelid) oedema. If side effects occur, Econor containing food should be immediately removed; severely affected pigs should be moved to clean, dry pens and given appropriate treatment.What are the precautions for the person who gives the medicine or comes into contact with the animal?Avoid direct contact with the skin, mouth and nose when mixing Econor and handling the final feed.Econor has been developed especially for pigs and is not for use in humans. However, if Econor is accidentially consumed by a person, seek medical advice immediately and show the product label. People known to be allergic to valnemulin should use Econor with caution.What is the time to allow before treated pigs can be slaughtered and the meat used for human consumption (withdrawal period)?After the last administration of Econor (in the feed), pigs should not be slaughtered for one day.Why has Econor been approved?The Committee for Medicinal Products for Veterinary Use (CVMP) agreed that the benefits of Econor are greater than any risks to prevent or treat a range of intestinal and respiratory diseases in pigs. The Committee recommended that Econor should be given a marketing authorisation. The benefit-risk balance may be found in module 6 of this EPAR.Other information about Econor:The European Commission granted a marketing authorisation valid throughout the European Union, for Econor to Novartis Animal Health Austria GmbH on 14 October 1998. Information on the prescription status of this product may be found on the label of the carton.This summary was last updated on 06.01.2011.。